BANK VONTOBEL AG | Market Closed - Swiss Exchange 16:20:00 03/07/2024 BST | ||
| 100.5 CHF | -0.50% |
|
| Current month | -0.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 100.5 | -0.50% |
Delayed Quote Swiss Exchange
Last update July 03, 2024 at 04:20 pm
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| RMA0EV | |
| ISIN | CH1341853393 |
| Date issued | 07/06/2024 |
| Strike | 984 kr |
| Maturity | 08/06/2026 (705 Days) |
| Parity | 0.98 : 1 |
| Emission price | 100 CHF |
| Emission volume | N/A |
| Settlement | both |
| Currency | CHF |
Technical Indicators
| Highest since issue | 101 CHF |
|---|---|
| Lowest since issue | 100.5 CHF |
| Spread | 8 CHF |
| Spread % | 0.80% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- RMA0EV Certificat
